Eoflow (294090) Q4 2024 earnings summary

Executive summary

• Specializes in wearable drug delivery devices, notably insulin pumps and artificial pancreas systems, with a focus on diabetes care and expansion into non-insulin drug delivery and wearable kidney devices.

• Faced significant legal challenges, including a major intellectual property lawsuit in the US and Europe, resulting in a $462 million damages verdict and ongoing appeals.

• Experienced a failed acquisition by Medtronic, leading to contract termination and subsequent arbitration for break-up fees.

Financial highlights

• 2024 consolidated revenue was KRW 5,031 million, down 23.7% year-over-year; operating loss widened to KRW 61,010 million.

• Net loss for 2024 was KRW 64,726 million, with negative equity of KRW 33,229 million and a sharp drop in cash to KRW 3,387 million.

• Gross margin remained negative, and the company has posted consecutive years of significant losses.

• Cash flows from operations were negative at KRW -41,683 million; financing activities provided KRW 29,572 million.

Outlook and guidance

• Management highlights ongoing regulatory and legal risks, with continued focus on product development and international expansion.

• Plans to address liquidity through asset sales, convertible bond conversions, loan extensions, and potential equity raises.

• Product pipeline includes next-generation artificial pancreas and wearable kidney devices, with launches targeted for 2025–2026.